Shareholders Approve Psyga Bio Acquisition, $1.5M Financing, and Massive Share Capital Increase
XTLB sits 17% above its 52-week low of $2.01.
Summary
XTL Biopharmaceuticals shareholders approved the acquisition of Psyga Bio, a $1.5 million private placement, and a significant increase in authorized share capital, enabling the company to proceed with its strategic plans and address its financial needs.
Key Events · Corporate Governance and Compliance · XTLB
-
Acquisition of Psyga Bio Approved
Shareholders approved the acquisition of 80-100% of Psyga Bio Ltd., a key strategic move previously announced on April 29, 2026.
-
$1.5 Million Private Placement Approved
A private placement of up to $1.5 million from Mr. Alexander Rabinovitch and/or other investors was approved, conditional upon the Psyga Bio acquisition. This financing is substantial for the company's size and critical for its operations.
-
Authorized Share Capital Increased
The company's authorized share capital was approved to increase by 2.9 billion shares, bringing the total to 5.8 billion ordinary shares. This provides the necessary capacity for the acquisition and financing, but indicates significant potential future dilution.
-
Auditor Appointment Approved
Shareholders approved the appointment of BARZILY & CO. C.P.A as the independent registered public accounting firm for the year ending December 31, 2025.
Analysis · XTLB · Life Sciences
This filing confirms shareholder approval for critical strategic and financial initiatives. The acquisition of Psyga Bio and the associated $1.5 million private placement are essential for XTL Biopharmaceuticals to execute its new business strategy and secure necessary funding, especially as the company faces Nasdaq delisting threats. The approval of a massive increase in authorized share capital provides the necessary headroom for these transactions, though it signals significant potential future dilution.
At the time of this filing, XTLB was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $2.01 to $10.28. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.